Literature DB >> 33511998

Effect of the unfolded protein response and oxidative stress on mutagenesis in CSF3R: a model for evolution of severe congenital neutropenia to myelodysplastic syndrome/acute myeloid leukemia.

Adya Sapra1, Roman Jaksik2, Hrishikesh Mehta1, Sara Biesiadny3, Marek Kimmel2,3, Seth J Corey2.   

Abstract

Severe congenital neutropenia (SCN) is a rare blood disorder characterised by abnormally low levels of circulating neutrophils. The most common recurrent mutations that cause SCN involve neutrophil elastase (ELANE). The treatment of choice for SCN is the administration of granulocyte-colony stimulating factor (G-CSF), which increases the neutrophil number and improves the survival and quality of life. Long-term survival is however linked to the development of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML). About 70% of MDS/AML patients acquire nonsense mutations affecting the cytoplasmic domain of CSF3R (the G-CSF receptor). About 70% of SCN patients with AML harbour additional mutations in RUNX1. We hypothesised that this coding region of CSF3R constitutes a hotspot vulnerable to mutations resulting from excessive oxidative stress or endoplasmic reticulum (ER) stress. We used the murine Ba/F3 cell line to measure the effect of induced oxidative or ER stress on the mutation rate in our hypothesised hotspot of the exogenous human CSF3R, the corresponding region in the endogenous Csf3r, and Runx1. Ba/F3 cells transduced with the cDNA for partial C-terminal of CSF3R fused in-frame with a green fluorescent protein (GFP) tag were subjected to stress-inducing treatment for 30 days (~51 doubling times). The amplicon-based targeted deep sequencing data for days 15 and 30 samples show that although there was increased mutagenesis observed in all the three genes of interest (partial CSF3R, Csf3r and Runx1), there were more mutations in the GFP region compared with the partial CSF3R region. Our findings also indicate that there is no correlation between the stress-inducing chemical treatments and mutagenesis in Ba/F3 cells. Our data suggest that oxidative or ER stress induction does not promote genomic instability, affecting partial C-terminal of the transduced CSF3R, the endogenous Csf3R and the endogenous Runx1 in Ba/F3 cells that could account for these targets to being mutational hotspots. We conclude that other mechanisms to acquire mutations of CSF3R that help drive the evolution of SCN to MDS/AML.
© The Author(s) 2021. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society.All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33511998      PMCID: PMC7846132          DOI: 10.1093/mutage/geaa027

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  28 in total

1.  The Site Frequency Spectrum for General Coalescents.

Authors:  Jeffrey P Spence; John A Kamm; Yun S Song
Journal:  Genetics       Date:  2016-02-16       Impact factor: 4.562

2.  Elastase inhibitors as potential therapies for ELANE-associated neutropenia.

Authors:  Vahagn Makaryan; Merideth L Kelley; Breanna Fletcher; Audrey Anna Bolyard; A Andrew Aprikyan; David C Dale
Journal:  J Leukoc Biol       Date:  2017-07-28       Impact factor: 4.962

3.  Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: Results of a long-term survey.

Authors:  Manuela Germeshausen; Matthias Ballmaier; Karl Welte
Journal:  Blood       Date:  2006-09-19       Impact factor: 22.113

4.  CpG mutation rates in the human genome are highly dependent on local GC content.

Authors:  Karl J Fryxell; Won-Jong Moon
Journal:  Mol Biol Evol       Date:  2004-11-10       Impact factor: 16.240

5.  Clinical relevance of point mutations in the cytoplasmic domain of the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia.

Authors:  N Tidow; C Pilz; B Teichmann; A Müller-Brechlin; M Germeshausen; B Kasper; P Rauprich; K W Sykora; K Welte
Journal:  Blood       Date:  1997-04-01       Impact factor: 22.113

6.  Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group.

Authors:  Jean Donadieu; Thierry Leblanc; Brigitte Bader Meunier; Mohamed Barkaoui; Odile Fenneteau; Yves Bertrand; Micheline Maier-Redelsperger; Marguerite Micheau; Jean Louis Stephan; Noel Phillipe; Pierre Bordigoni; Annie Babin-Boilletot; Philippe Bensaid; Anne Marie Manel; Etienne Vilmer; Isabelle Thuret; Stephane Blanche; Eliane Gluckman; Alain Fischer; Françoise Mechinaud; Bertrand Joly; Thierry Lamy; Olivier Hermine; Bruno Cassinat; Christine Bellanné-Chantelot; Christine Chomienne
Journal:  Haematologica       Date:  2005-01       Impact factor: 9.941

7.  Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis.

Authors:  Julia Skokowa; Doris Steinemann; Jenny E Katsman-Kuipers; Cornelia Zeidler; Olga Klimenkova; Maksim Klimiankou; Murat Unalan; Siarhei Kandabarau; Vahagn Makaryan; Renee Beekman; Kira Behrens; Carol Stocking; Julia Obenauer; Susanne Schnittger; Alexander Kohlmann; Marijke G Valkhof; Remco Hoogenboezem; Gudrun Göhring; Dirk Reinhardt; Brigitte Schlegelberger; Martin Stanulla; Peter Vandenberghe; Jean Donadieu; C Michel Zwaan; Ivo P Touw; Marry M van den Heuvel-Eibrink; David C Dale; Karl Welte
Journal:  Blood       Date:  2014-02-12       Impact factor: 22.113

8.  Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia.

Authors:  F Dong; R K Brynes; N Tidow; K Welte; B Löwenberg; I P Touw
Journal:  N Engl J Med       Date:  1995-08-24       Impact factor: 91.245

9.  Neutropenia-associated ELANE mutations disrupting translation initiation produce novel neutrophil elastase isoforms.

Authors:  Timothy Tidwell; Jeremy Wechsler; Ramesh C Nayak; Lisa Trump; Stephen J Salipante; Jerry C Cheng; Jean Donadieu; Taly Glaubach; Seth J Corey; H Leighton Grimes; Carolyn Lutzko; Jose A Cancelas; Marshall S Horwitz
Journal:  Blood       Date:  2013-11-01       Impact factor: 22.113

10.  Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations.

Authors:  Kevin Watanabe-Smith; Jamila Godil; Anupriya Agarwal; Cristina Tognon; Brian Druker
Journal:  Oncotarget       Date:  2017-02-21
View more
  1 in total

1.  G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial.

Authors:  Tomáš Stopka; Lubomír Minařík; Nina Dusilková; Michal Pešta; Vojtěch Kulvait; Martin Špaček; Zuzana Zemanová; Marta Kalousová; Anna Jonášová
Journal:  Blood Cancer J       Date:  2022-07-07       Impact factor: 9.812

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.